When EP4 antagonists are used, breast cancer metastasis is inhibited; this effect is closely associated with a decrease in the expression of major histocompatibility complex class I antigens in tumor cells, as well as an increase in NK cell recognition 144. The gene discussed is PTGER4; the disease is neoplasm.